



Keytruda[®] (pembrolizumab) – New warning

- On November 29, 2017, the FDA approved an update to the *Warnings and Precautions* section of the [Keytruda \(pembrolizumab\)](#) drug label regarding increased mortality in patients with multiple myeloma (MM) when Keytruda is added to a thalidomide analogue and [dexamethasone](#).
- Keytruda is indicated for the treatment of melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, and gastric cancer.
- In two randomized clinical trials in patients with MM, the addition of Keytruda to a thalidomide analogue plus dexamethasone, a use for which no programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PDL1) blocking antibody is indicated, resulted in increased mortality.
- Treatment of patients with MM with a PD-1 or PDL1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.